{"id":"W4384520841","doi":"10.1200/jco.22.02760","title":"Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Bevacizumab; Medicine; Oxaliplatin; FOLFOX; Folinic acid; Internal medicine; Colorectal cancer; Oncology; Clinical endpoint; Chemotherapy; Placebo; Capecitabine; Hazard ratio; Progression-free survival; Surgery; Randomized controlled trial; Cancer; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00443902,0.000211782,0.0030807,0.0004081042,0.00004952099,0.000009192484,0.0001018907,0.000119317,0.0001613005],"category_scores_gemma":[0.001302371,0.0001247239,0.0003316078,0.0007289452,0.0002055023,0.0000683035,0.00001715447,0.000596211,0.000003865957],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004092772,"about_ca_system_score_gemma":0.001616066,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006169221,"about_ca_topic_score_gemma":0.005328243,"domain_scores_codex":[0.996039,0.0007741612,0.002227839,0.0002422957,0.0004602181,0.0002565028],"domain_scores_gemma":[0.9934811,0.004748355,0.001207866,0.0001065966,0.0003136087,0.0001424656],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7555528,0.01696337,0.0880008,0.00001726229,0.001379568,0.001921171,0.001895388,0.0003839817,0.00002475509,0.000009848652,0.0001349691,0.1337161],"study_design_scores_gemma":[0.7423705,0.07871794,0.1744687,0.0001217803,0.000316125,0.00003011886,0.000700966,0.002278275,0.00005064993,0.0001950785,0.0006481174,0.0001017434],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9851435,0.0005250965,0.00001393943,0.01159435,0.0003648781,0.002073331,0.000003589123,0.0000173378,0.0002640078],"genre_scores_gemma":[0.9952333,0.003136981,0.0001993278,0.0009149828,0.0001362908,0.0002664523,0.000006104988,0.00002204932,0.00008448571],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1336143,"threshold_uncertainty_score":0.5086092,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1009913211866394,"score_gpt":0.4850312222814466,"score_spread":0.3840399010948072,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}